Rakuten Investment Management Inc. increased its stake in Boston Scientific Corporation (NYSE:BSX – Free Report) by 118.1% during the 4th quarter, Holdings Channel reports. The fund owned 194,985 shares of the medical equipment provider’s stock after purchasing an additional 105,564 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Boston Scientific were worth $18,672,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the fourth quarter valued at $26,000. Colonial Trust Co SC raised its stake in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares in the last quarter. Bangor Savings Bank raised its stake in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund acquired a new stake in Boston Scientific in the fourth quarter valued at $29,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Boston Scientific
In other news, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 9,800 shares of company stock valued at $554,012 in the last quarter. 0.34% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on Boston Scientific
Boston Scientific Stock Performance
Shares of BSX stock opened at $46.69 on Tuesday. The stock has a market capitalization of $69.39 billion, a PE ratio of 19.53, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56. Boston Scientific Corporation has a 52-week low of $45.99 and a 52-week high of $109.50. The stock’s 50-day moving average price is $56.05 and its 200 day moving average price is $74.40. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current year.
Boston Scientific declared that its Board of Directors has authorized a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Further Reading
- Five stocks we like better than Boston Scientific
- Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
